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Abstract To assess the clinical validity of individual
DSM-IV criteria for hypomania. In an international sample
of 5,635 patients with major depressive episodes (Bridge
Study), DSM-IV criteria for hypomania (stem questions,
number and quality of symptoms, duration and exclusion
criteria) were systematically assessed and their validity
analysed on the basis of clinical data including family
history, course, and other clinical characteristics. Three
stem questions for hypomania, irritability, elevated mood
and the added question of increased activity, showed
comparable validity. The results support the current DSM-
IV requirement for a higher symptom threshold (4 of 7
hypomanic symptoms) in cases of irritable mood. Longer
durations of hypomanic episodes were associated with
higher scores on all validators. The results did not support
the DSM-IV durational requirements for hypomanic epi-
sodes (4 days) and manic episodes (7 days). Brief hypo-
manic episodes of 1, 2 or 3 days were valid and would
meet validity criteria for inclusion. The three exclusion
criteria in DSM-IV (hypomania due to the use of antide-
pressants or of other substances, or to other medical con-
ditions) were found to exclude patients with bipolar
depression and should therefore not be retained. These
results support several revisions of the DSM-IV concept of
hypomanic episodes: specifically, the inclusion of
increased activity as a gate question, the inclusion of 1 or 2
to 3-day episodes and the elimination of all exclusion
criteria.
Keywords Hypomania  Diagnosis  DSM criteria 
Validity  Bridge study
Introduction
Epidemiological studies have reported lifetime prevalence
rates for major mood disorders of 20% (NCS-R (USA)
conducted over ten years [11]), 27.45% (EDSP Study
(Munich) ten years) [18] and 23.6% (NEMESIS (Nether-
lands) 3 years) [5, 7]. All three studies identified 80–90%
of such cases as DSM major depressive disorders (MDD)
and only about 10–20% as bipolar disorders (BPD).
However, recent re-analyses of the EDSP Study [21] and
the NCS-R [4] have demonstrated that this simple
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dichotomy is questionable and that hypomanic syndromes
that do not meet DSM-IV criteria for bipolar-II are present
in about 40% of subjects with DSM-IV MDD. Each of
these longitudinal epidemiological studies applied the
comprehensive international diagnostic interview (CIDI),
which is tailored to the DSM-IV and hence cannot provide
detailed information about the validity of the diagnostic
criteria for hypomanic episodes used for the definition of
bipolar-II disorders. To address this limitation in the
studies, we report results from the large, multinational
Bridge Study, which applied a descriptive, bottom-up
approach to assess for hypomania and included an opera-
tionally defined alternative set of diagnostic criteria for
bipolarity in patients presenting with a major depressive
episode [3].
Methods
The Bridge Study (Bipolar Disorders: Improving Diag-
nosis, Guidance, and Education) is a cross-sectional
diagnostic investigation of 5,635 depressed patients car-
ried out in 18 countries in Europe, Asia and North Africa
between April 2008 and May 2009. A total of 521
community- and hospital-based psychiatrists recruited
consecutively all adult patients who came for evaluation
with a diagnosis of major depressive episode according to
DSM-IV criteria [6]. At the study evaluation, participating
psychiatrists completed an assessment covering patients’
clinical features, sociodemographic variables, diagnosis,
medical history, treatment and comorbid psychiatric dis-
orders. Separate sections on hypomania/mania, and the
MINI DSM-IV diagnostic interview [12] were applied.
These methods enabled a diagnosis of bipolar disorder to
be assigned when justified by three different diagnostic
algorithms: DSM-IV-TR, modified DSM-IV (no exclusion
criteria applied) and a new bipolarity specifier [3, 6].
Finally, each patient completed the Hypomania Checklist
for self-assessment [18]. The study was carried out by
Sanofi-Aventis in co-operation with an advisory board [4,
6, 11, 13, 21].
The goal of this analysis of the Bridge Study data was
limited to assessing the clinical validity of the individual
DSM-IV criteria for hypomania. We applied clinical vali-
dators which could be assessed at the initial interview, such
as a family history of hypomania/mania (assessed by a
direct, simple question), age of onset and course (recur-
rence, progression, free intervals, seasonality) and addi-
tional clinical characteristics, e.g. mood lability, psychotic
features, comorbidity, resistance to treatment and hospi-
talisation. Family history among first degree relatives,
although strongly supported by published studies, has one
limitation as a validator, as it tends to be under-reported
both by patients and by controls (false negatives), conse-
quent to incomplete information, particularly in a one visit
appointment.
A DSM-IV diagnosis of mania and hypomania requires
a distinct episode of elevated, expansive, or irritable mood
(criterion A). As in the Zurich Study, in the Bridge Study,
we added increased activity as a third A criterion because
patients are more likely to recognise changed levels of
activity (at least as prominent in bipolar disorder as mood
changes) whereas some persons lack self awareness of their
changes in mood. Because the data were collected when
the patients were evaluated, all information on previous
history is by definition retrospective. The study is therefore
a descriptive one.
The analyses conducted were based on the structure of
DSM-IV, which distinguishes the following diagnostic
elements of bipolarity:
– presence of a distinct period with the following criteria:
A1: persistently elevated, expansive, or irritable
mood
A2: duration of episode: at least 4 days
B: number of manic symptoms
C-E: consequences
F: exclusion criteria:
F1) episode due to antidepressants
F2) episode due to other substances
F3) episode due to another medical condition
The analyses focus on (1) the Category A criteria (’gate’
questions for hypomania, including also increased activity,
(2) the duration of hypomanic episodes (assessed as 1,
2–3 days, 4–6 days, 7 days or more and 1 month or more
in length)), (3) the number and quality of symptoms, and
(4) the three exclusion criteria F.
Statistics
Groups were statistically compared using v2—tests for
percentages and Kruskal–Wallis tests for continuous vari-
ables. The analysis involved many tests of statistical sig-
nificance, raising the problem of type I errors, i.e. of tests
being statistically significant by chance alone. We offer a
correction for multiple comparisons, but we nevertheless
present the uncorrected p-values because, by showing only
corrected values, important findings may be missed.
A Bonferroni-corrected threshold for statistical significance
is reported with each table. The correction can be applied
by simply raising the level of statistical significance to this
threshold. All tests were two-sided. Analyses were carried
out in Stata 10.2 for Windows.
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Results
Gate questions (criterion A1): irritability, elevated
mood and (new) increased activity
The recruiting psychiatrists answered three gate questions
about their patients’ current clinical status with yes/no
responses: (1) episode of elevated mood, (2) episode of
irritability, (3) episode of increased activity (work, social,
motor). Since patients could present with any or none of
the three criteria, eight subgroups were possible. Of the
5,602 patients with major depressive episodes, 3,618
(64.6%) met one or more of the three criteria; of those,
1,021 patients were assessed positively on only one gate
question; the remaining 2,597 met two or three. Irritability
was reported three times more often than euphoria/eleva-
tion or increased activity alone.
Of special interest are patients with a major depressive
episode who met only one of the three gate questions. A
total of 610 (10.9%) were assessed as exclusively irritable
(i.e. not euphoric/elevated etc.), 211 (3.8%) as exclusively
more active and 200 (3.6%) as exclusively euphoric/ele-
vated in mood (Table 1). In addition, we defined a pure
depressed group of 1,984 patients with major depressive
disorder (group 0 in Table 1) who scored negatively on all
three gate questions. As shown in Table 1, this group dif-
fered significantly (P \ 0.0001) from the three positive
groups with regard to most of the validators and clinical
characteristics of bipolarity, with the exception of a history
of suicide attempts (P \ 0.09). Group 0 also differed sig-
nificantly in its total score on the Hypomania Checklist 32.
Depressed patients with irritable mood did not differ
statistically from those with euphoria or increased activity
in the validators (statistics not shown). There was no sta-
tistical difference in terms of family history and course
between the three positive groups. Patients with irritable
mood experienced fewer episodes of hypomania while
taking antidepressants but manifested more mood lability
and mixed states.
Total number of manic symptoms by gate questions
Figure 1 presents the medians, quartiles and ranges of the
total number of manic symptoms for each of the eight
permutations of the three gate questions. The more com-
plex the permutation of the gate questions, the higher the
number of diagnostic hypomanic symptoms. For example,
the depressed patients with irritable mood alone had a
median of only two hypomanic symptoms, those with only
elevated mood or increased activity had three, and the
Table 1 Major depressive episode patients—clinical characteristics of pure groups: irritable mood, increased activity, elated mood
Major depressive episodes
Positive gate question for mania
None Irritability only Increased activity only Elevated mood only
(0) (1) (2) (3) P (0 vs. 1/2/3) P (1–3)
N 1984 610 211 200
% % % %
Family history of hypomania 4.6 10.6 14.1 15.1 0.0005 0.16
Early onset \30 years 34.3 43.3 37.0 47.0 0.0005 0.11
C2 mood episodes 51.7 66.8 65.7 73.4 0.0005 0.17
Free intervals 53.7 62.7 64.7 68.0 0.0005 0.45
Recurrence 64.6 79.6 77.3 82.5 0.0005 0.43
Hospitalisation 23.4 28.4 23.2 36.3 0.0005 0.14
Seasonality 13.9 26.4 25.6 28.6 0.0005 0.74
Hypomanic switches 1.6 29.8 32.2 36.0 0.0005 0.0005
Mixed state 15.2 43.2 33.2 25.6 0.0005 0.0005
Mood lability 16.1 43.2 33.5 31.8 0.0005 0.004
AD non-responder 17.6 25.5 22.3 16.7 0.0005 0.04
Atypical depression 15.9 25.3 20.4 23.0 0.0005 0.34
History of suicide attempts 22.3 26.3 19.4 26.9 0.09 0.10
HCL-32 total score 7.2 10.5 14.1 14.6 0.0005 0.0001
Bonferroni threshold P = 0.0018
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combined groups had four, five or six symptoms. Figure 1
also indicates that the DSM-IV symptom threshold for
caseness for a hypomanic episode in the depressed patients
with irritable mood (4 or more of 7 manic symptoms)
would exclude about 80% of the 610 subjects. And the
current threshold of 3 of 7 symptoms would exclude 50%
of the depressed patients with euphoria or increased
activity alone as cases.
Hypomanic episodes with 3 of 7 symptoms
and consequences by gate questions
The following analyses include all major depressive epi-
sode patients assessed positively on the gate questions for
hypomania, having 3 of 7 manic symptoms and meeting
DSM-IV criteria C, D, E (consequences) for a hypomanic
episode (Table 2).
Manic symptom profiles
The hypomanic symptom profiles for patients grouped by
gate questions are shown in Table 2. Consistent with the
findings reported in the previous section, subjects with
three positive gate questions had the highest scores on each
of the seven diagnostic symptoms, the most prevalent of
which were increased activity/agitation, increased talka-
tiveness and less need for sleep.
Consequences of hypomanic behaviour
The results in Table 2 indicate the systematic increase of
consequences across the subgroups of patients with major
depressive episodes, i.e. the higher the number of positive
gate questions, the steeper the rates of impairment, of
ambulatory treatment and of hospitalisations.
It is interesting that a change in behaviour was observed
in 50 to 80%, whereas marked impairment rates were lower
(20 to 65%) and almost identical to rates of ambulatory
treatment.
Clinical validity
A positive family history for hypomania/mania strongly
increased with the quality and number of gate questions.
Similar trends are present in course characteristics, early
onset, recurrence, illness progression and seasonality. The
independent self-assessment of hypomania by the patients
confirmed the trends found in the psychiatric interview
data.
Clinical validity of symptom thresholds for caseness
We conducted an additional analysis (not shown) applying
a symptom threshold of 2 or more of 7 manic symptoms
that confirmed the increase in bipolar caseness. For most
clinical characteristics, there was a trend to slightly better
validity using the higher (3 ?/7) compared to the lower
(2 ?/7) symptom threshold, but the latter still differed
markedly from the pure MDD group (0 group) in the val-
idators. However, the differences between the two diag-
nostic thresholds seemed inconclusive therefore, we make
no choice between the two.
Duration of hypomanic episodes as a diagnostic
criterion
In all patients with a major depressive episode, the length
of potential hypomanic episodes (identified only by the
gate questions) was assessed as 1 day, 2–3 days, 4–6 days,
7 or more days and 1 month or more. As a consequence of
missing data for pure MDD cases, the total N was 3,635.
Hypomania of 2–3 days duration was more common than
episodes of 4–6 days’ duration (Table 3). The rates for the
validators and clinical characteristics for bipolarity
increased in direct relationship to the duration of hypo-
manic episodes. However, all bipolar durational subgroups,
including those subjects whose hypomanic episodes lasted
only one day, differed significantly from the pure MDD
group without hypomanic features.. Patients’ self-assess-
ment of the number of days spent in hypomania over the
past year resulted in a median of 20 days for each of the
different episodes lengths (1 day, 2–3 days, 4–6 days,
7 ? days). These results indicate that a definition of a
minimum hypomanic episode duration of 2 or 4 days is an
arbitrary choice, and one not based on data.
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Fig. 1 Box plot of the sum of hypomanic symptoms (Total: 7) by
permutation of gate questions. Shown are medians, 25th and 75th
percentiles, upper and lower adjacent values and outliers, sx
symptoms, irrit irritable mood, activ increased activity, elev elevated
mood
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Exclusion criteria for bipolarity
We investigated whether DSM-IV exclusion criterion F
rests on good evidence. For instance, do patients with a
major depressive episode who develop hypomania under an
antidepressant or other substances have unipolar or bipolar
depressive disorder? We hypothesise that any causal attri-
bution is uncertain.
In this study, 1,553 (32.8%) of 4,732 DSM-IV MDD
patients met exclusion criterion F. About 1,392 (89.6%) of
Table 2 Major depressive episode patients meeting the following three diagnostic criteria: gate question, consequences and 3 out of 7 symptoms
of mania
Positive gate questions None irrit.
only
activ.
only
elev.
only
irrit. ? activ. elev. ? irrit. elev.
? activ.
elev.
? irrit.
? activ.
P (0 vs.
1/2/3)
(0) (1) (2) (3) (4) (5) (6) (7)
N 1988 177 104 110 185 126 521 1422
% % % % % % % %
Diagnostic symptoms
Grandiosity 0.5 11.3 28.2 46.7 33.0 51.4 67.3 81.9
Less need for sleep 2.4 34.7 53.1 56.8 66.5 64.9 74.2 87.9
More talkative 1.6 28.9 61.7 72.9 65.7 80.8 89.0 93.5
Flight of ideas 0.5 17.2 24.9 36.2 36.0 44.7 50.7 72.5
More distractable 3.3 57.2 32.2 44.7 62.8 66.1 54.1 78.4
Increased goal-directed or
psychomotor activity
3.5 53.7 91.4 73.2 89.5 80.2 91.0 97.1
Increased pleasure- and risk-seeking 0.5 11.4 17.7 31.7 34.2 44.1 42.3 66.4
Consequences
Unequivocal, observable change 37.3 38.9 47.0 56.9 62.0 69.6 82.8
Marked impairment 38.0 20.4 24.0 38.7 49.7 30.5 65.2
Observable by others 54.2 50.7 53.5 66.2 75.0 73.7 87.1
Hospitalisation 11.4 6.6 11.0 11.6 21.5 18.7 39.5
Ambulatory treatment 30.7 17.4 23.2 39.9 43.8 33.0 57.7
Clinical validators and characteristics
Family history of hypomania 4.6 15.5 19.4 19.4 23.1 25.6 23.5 33.4 0.0005
Course
Early onset \ 30 years 34.2 52.9 41.3 53.7 57.2 66.7 48.0 62.6 0.0005
C2 mood episodes 51.7 74.9 72.1 80.7 77.5 84.8 82.9 91.4 0.0005
Free intervals 14.2 22.1 16.5 15 19.2 15.1 11.5 15.4 0.0005
Illness progression of mood episodes 64.6 85.7 81.7 92.7 87.3 89.6 90.5 95.3 0.0005
Seasonality of mood episodes 14.0 37.1 26.9 32.4 36.5 47.6 36.2 44.2 0.0005
Hospitalisation 1.1 21.1 11.5 19.3 15.6 27.4 23.3 42.1 0.0005
Manic/hypomanic switches 0.7 16.2 26.5 34.9 24.0 32.5 35.3 44.7 0.0005
Mood lability 16.1 58.8 33.3 40.7 55.4 66.1 46.3 61.9 0.0005
Mixed state/mood lability 15.2 55.7 35.0 32.4 54.5 54.6 33.9 52.4 0.0005
Resistance to treatment 17.6 33.3 29.4 17.6 26.9 28.0 21.1 28.5 0.0005
History of suicide attempts 22.3 33.1 25 24.8 36.3 36.8 28.5 36.5 0.008
Self-assessed hypomania Means Means Means Means Means Means Means Means
Sum score HCL (32 items) 7.2 14.3 17.3 16.8 16.1 17.8 18.9 20.9 0.0001
Score F1-revised, HCL (20 items) 5.7 10.1 13.1 12.5 11.6 12.5 14.6 14.9 0.0001
Score F2-revised, HCL (12 items) 1.6 4.1 4.1 4.3 4.4 5.4 4.3 6.0 0.0001
Bonferroni threshold P = 0.0018
irrit irritable mood; activ increased activity; elev elevated mood
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them became hypomanic under antidepressants (F1) and a
further 208 under other substances or due to medical causes
(criterion F2 and F3).
Lifetime switches to hypomania under antidepressants
Table 4 compares 3,137 MDD patients who experienced
no switch with the three subgroups who switched; 903
patients with DSM bipolar disorder (BPD) are listed for
visual comparison.
The two MDD subgroups (with switches and without
switches under antidepressants (1 vs. 2) differed greatly
with regard to the validators. In the group who switched, a
family history for hypomania/mania was three times more
common and the first symptoms occurred earlier. Similarly,
patients in the AD switch group had more episodes and
more free intervals between episodes, which is comparable
to the BPD group. The mean scores of self-assessed
hypomanic symptoms (HCL-32 R1) in the switch group
were almost double those in the pure MDD group.
Lifetime switches to hypomania under other
circumstances
The 144 patients whose switches were due to other sub-
stances and the 59 in whom they were due to a general
medical condition (subgroups 3 and 4) also differed greatly
from the pure MDD case, having higher rates of family
history for hypomania, earlier onset and typical course
characteristics of bipolar depression, including seasonality,
mixed states and mood lability.
In the aggregate, these validity data for the three groups
who developed hypomania align them much more closely
with the BPD than with the pure MDD group.
Discussion
These analyses, from a large, multinational and broadly
representative clinical sample, indicate that the clinical
validity of increased activity as a gate criterion for bipolar
disorders is comparable to that of elevated/expansive
mood. The addition of activity identified an additional 6%
of cases of sub-threshold hypomania among patients with a
major depressive episode. The addition of increased
energy/activity is currently being considered for the defi-
nition of a hypomanic episode in the proposed draft revi-
sions to DSM-5, an option which the results of the present
study support.
The lower specificity of irritability as a gate criterion of
bipolarity is consistent with the findings of Rich et al. [15]
in paediatric bipolar disorders and with some of the
Table 3 Major depressive episode patients: clinical characteristics and validators by duration of hypomanic episode
Variable Unipolar
MDD
Duration of hypomanic episodes
1 day 2–3 days 4–6 days 7 ? days 1 month? P (0 vs. 1) P (0 vs. 2) P (1–5)
N 1988 285 626 409 1096 1219
(0) (1) (2) (3) (4) (5)
% % % % % %
Family history of hypomania 4.6 11.0 16.7 21.4 24.5 27.4 0.0005 0.0005 0.0005
Early onset \30 years 34.3 50.7 51.7 56.3 53.0 52.8 0.0005 0.0005 0.60
C2 mood episodes 51.7 64.7 69.0 81.2 84.1 85.2 0.0005 0.0005 0.0005
Illness progression of mood episodes 64.6 75.6 78.8 89.0 90.5 92.3 0.0005 0.0005 0.0005
Seasonality of mood episodes 14.0 22.8 27.4 39.6 41.0 39.4 0.0005 0.0005 0.0005
Manic/hypomanic switches 0.7 8.7 14.0 27.1 37.9 35.2 0.0005 0.0005 0.0005
Mixed state/mood lability 15.2 36.6 42.0 44.0 48.1 41.7 0.0005 0.0005 0.002
Mood lability 16.1 28.6 39.1 50.0 57.0 53.1 0.0005 0.0005 0.0005
Resistance to treatment 17.6 22.4 22.2 26.6 25.4 25.6 0.080 0.008 0.35
Atypical depression 15.9 22.8 23.8 28.6 31.5 28.2 0.001 0.0005 0.003
History of suicide attempts 22.3 31.0 29.1 28.9 33.2 33.0 0.001 0.0005 0.33
Self-assessed highs Means Means Means Means Means Means
Sum score HCL (32 items) 7.2 13.0 14.8 16.6 17.6 19.0 0.0001 0.0001 0.0001
Score F1-revised, HCL (20 items) 5.7 9.9 11.0 12.4 13.0 13.9 0.0001 0.0001 0.0001
Score F2-revised, HCL (12 items) 1.6 3.3 3.8 4.3 4.6 5.1 0.0001 0.0001 0.0001
Days/past year in hypomania (medians) 7 20 20 20 20 45 0.0001 0.0001 0.0001
Bonferroni threshold P = 0.0011
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considerations raised by an ECNP expert consensus doc-
ument [10]. Depressed patients with irritable mood repor-
ted on average one fewer diagnostic manic symptom than
did patients with euphoria or increased activity. This
observation would support the DSM-IV requirement of a
larger number of diagnostic manic symptoms when only
irritability is present. The data also confirm the clinical
relevance of the current DSM-IV criteria for the conse-
quences (C, D, E) of hypomania.
The finding that the duration of hypomanic episodes is
systematically correlated with increasing validity is also
of interest. This result was present for each of the five
episode lengths we tested: 1 day, 2–3, 4–6 and 7 or
more days, and 1 month or more. We conclude that the
DSM-IV criteria of 4 days for hypomanic episodes and
7 days for manic episodes are not data based, and that
no clear cut-off for diagnosis based on this distribution
exists. Even patients with hypomanic episodes lasting
only 1 day differed markedly from those with pure major
depressive disorder, thus confirming the existence and
validity of brief hypomania (defined by 1–3 day epi-
sodes) [1, 2]. For DSM-5, a conservative decision would
be to include hypomanic episodes of 2–3 days as clini-
cally valid. Such a decision would support concerns
raised by authorities in child and adolescent psychiatry
[13]. However, the data from this study clearly favour a
1-day duration with a median of 20 days of hypomania
over the past 12 months.
Our results show the DSM-IV exclusion criteria F1, F2,
F3 for a hypomanic/manic episode to be problematic. The
data suggest that in patients with major depressive epi-
sodes, an antidepressant-induced switch occurs mainly in
those with signs indicative of bipolarity (family history,
onset and course). In addition, MDD patients who switched
under ADs were characterised by higher rates of season-
ality of episodes, mixed states, mood lability, resistance to
antidepressants in the previous history, atypical depression,
history of suicide attempts, psychotic features and psy-
chiatric hospitalisation. This finding is in accordance with
the lack of statistical evidence that hypomanic episodes are
caused by antidepressants [8, 14]. In the proposed draft
revisions to DSM-5, a switch under antidepressants has
been removed as an exclusion criterion for defining a
hypomanic episode. This proposed change will greatly
reduce the heterogeneity of MDD and may result in greater
validity of the diagnostic criteria for bipolar-I [16, 19] and
especially for bipolar-II [20] disorders. These data also
suggest, in agreement with numerous studies, that switches
from major depressive episodes to hypomania due to other
substances or other medical conditions occur mainly in
Table 4 Pure MDD versus MDD with switch under antidepressants
Variable MDD MDD ?
switch AD
MDD ? switch
other subst.
MDD ? switch other
medical conditions
BPD P (1 vs. 2) P (2–4)
(1) (2) (3) (4) (5)
N 3137 1392 144 59 903
% % % % %
Family history of hypomania 7.7 25.9 22.0 27.1 30.9 0.0005 0.58
Early onset \30 years 38.4 53.0 65.2 50.0 60.6 0.0005 0.02
C2 mood episodes 55.8 91.2 79.0 62.1 88.1 0.0005 0.0005
Free intervals 57.2 80.6 70.4 65.5 84.5 0.0005 0.001
Illness progression of mood episodes 68.4 96.7 83.3 67.2 94.7 0.0005 0.0005
Seasonality of mood episodes 18.2 45.6 34.0 37.9 37.8 0.0005 0.02
Mixed state/Mood lability 23.7 47.4 44.6 42.9 46.0 0.0005 0.68
Mood lability 21.4 66.2 39.6 40.4 52.7 0.0005 0.0005
Resistance to treatment 17.3 34.6 25.0 12.3 21.7 0.0005 0.0005
Atypical depression 18.3 32.5 36.8 28.8 27.5 0.0005 0.47
History of suicide attempts 23.2 35.8 33.6 20.3 33.3 0.0005 0.05
Psychotic features 10.2 17.1 12.5 18.6 21.2 0.0005 0.35
Ever admitted to a psychiatric hospital 23.4 28.5 25.7 25.9 57.6 0.0005 0.67
Self-assessed highs Means Means Means Means Means
Sum score HCL (32 items) 9.6 18.0 19.4 16.2 20.2 0.0001 0.004
Score F1-revised, HCL (20 items) 7.5 13.3 13.2 11.6 14.6 0.0001 0.09
Score F2-revised, HCL (12 items) 2.2 4.8 6.2 4.6 5.6 0.0001 0.0001
Diagnostic classification by DSM-IV
Bonferroni threshold P = 0.0016
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subjects with characteristics of and a disposition for bipo-
larity (family history, etc.) [9, 17].
The changes to existing DSM criteria suggested by our
study are summarised in Table 5.
These results have both the strength and the limitation
that they are based on treated patient and not epidemio-
logical samples. This is mainly a strength as regards the
clinical generalisability of the findings. Moreover, the
sample is uniquely large and distributed evenly across three
continents and many countries, which increases the gen-
eralisability of the results. The methods were determined
by a group of experts in the diagnostic nomenclature, ill-
ness course and symptomatic characteristics of bipolar
disorders; the documentation of the treating doctors’ find-
ings was standardised. No test of inter-rater reliability
among the participating psychiatrists was carried out.
Conclusions
The current concept of DSM-IV major depressive disorder
is problematic, because it includes over one-third of
patients who actually have subthreshold bipolar disorders.
The data of the Bridge Study suggest that there should
be a broader definition of a hypomanic episode and
consequently of bipolar-II disorder. The addition of
increased activity as a primary requirement for eligibility
for diagnosis of hypomania/mania and bipolar disorder
appears to be a valid and readily applicable change that
would improve the accurate diagnostic identification of
patients presenting with major depressive episodes. The
exclusion criteria for hypomania (episode due to antide-
pressants, other substances or other medical reasons) are
not valid and should be discontinued. Brief hypomanic
episodes (1–3 days’ duration) exist and have a similar
validity to longer episodes. These suggested changes
(Table 5) would allow much earlier recognition and
treatment of bipolar disorder and reduce adverse conse-
quences of interventions that are not indicated for bipolar
disorders.
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